8-K: Scienture Holdings Secures Exclusive U.S. Rights to Commercialize REZENOPY Nasal Spray for Opioid Overdose

Scienture Holdings, through its subsidiary, has entered into an agreement with Kindeva Drug Delivery to exclusively commercialize REZENOPY (naloxone HCl) Nasal Spray 10mg in the U.S., a critical step in combating the opioid epidemic.

Summary

• Scienture Holdings, Inc. has secured exclusive U.S. rights to commercialize REZENOPY (naloxone HCl) Nasal Spray 10mg through an agreement with Kindeva Drug Delivery.
• The agreement grants Scienture the exclusive right to price, launch, promote, market, distribute, and educate the public on REZENOPY within the United States and its territories.
• The term of the agreement is 10 years from the date of first commercial sale, with automatic 1-year renewals unless terminated.
• Scienture is responsible for commercializing the product and has final authority over pricing, while Kindeva retains control of manufacturing and non-clinical/clinical studies.
• The initial supply price for REZENOPY is $9.20 per unit, with potential annual increases based on manufacturing costs.
• Scienture will pay Kindeva milestone payments, net sales share payments (10%, reduced to 8% upon generic entry), and NDA cost reimbursements.
• Minimum order quantities are set at 3 batches of 450,000 units per year starting in 2027, or a payment of $1.242 million per year.
• A joint steering committee will be formed to oversee and coordinate activities under the agreement.
• IQVIA data indicates a total annual sales of $189 million, unit volume of $10.0 million (eaches) for Naloxone in the US market.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook due to the exclusive commercialization rights and the potential to address the opioid crisis. However, the financial obligations and market risks temper the overall sentiment.

Positives

• Scienture gains a significant product to combat the opioid crisis.
• The exclusive rights provide a competitive advantage in the U.S. market.
• The agreement leverages Kindeva's manufacturing expertise.
• REZENOPY is the most potent (highest strength) version of naloxone HCl available in the market.
• Nasal delivery of Naloxone HCl has been widely recognized for its efficacy, ease of use, and accessibility, making it an essential tool for first responders, healthcare providers, and community programs.

Negatives

• Scienture is responsible for commercializing the product and has final authority over pricing, while Kindeva retains control of manufacturing and non-clinical/clinical studies.
• Scienture must meet minimum order quantities or pay a substantial annual fee.
• Profit-sharing payments include 5% of net sales until the total cumulative payments equals Kindevas cost of developing and receiving NDA approval of the Product, which was $12.8 million as of the date of the Agreement.

Risks

• The agreement can be terminated if the Product is withdrawn from the market due to FDA action or safety concerns.
• A mass tort liability action could lead to termination.
• Changes in the market or business conditions could compromise the Product's value.
• The entry of a third-party generic ANDA will reduce Scienture's net sales share.
• The company may not be able to successfully commercialize the product.

Future Outlook

Scienture intends to use the exclusive right and license to price, launch, promote, market, distribute, and educate the public on REZENOPY. The company is dedicated to collaborating with healthcare professionals, policymakers, and advocacy groups to enhance awareness, education, and distribution efforts.

Management Comments

• Narasimhan Mani, Ph.D., MBA, President of Scienture, LLC, stated, 'We are proud to take this significant step in strengthening our commitment to combating the opioid epidemic... Through this collaboration with a well established and strong partner like Kindeva, we now offer REZENOPY, a higher dose naloxone HCl option for communities, reinforcing our mission to deliver impactful healthcare solutions.'
• Shankar Hariharan, Ph.D., CEO of Scienture, LLC, added, 'This collaboration is not just about expanding our portfolio; it's about making a real difference in the fight against opioid addiction... By working alongside public health agencies and community organizations, we will drive meaningful change and save lives.'
• Milton Boyer, CEO of Kindeva, remarked, 'As part of our commitment to fast-tracking healthier tomorrows, we are thrilled to be joining forces with Scienture to bring this life-saving device to market... Our nasal drug delivery team has created a nasal spray that is quick and simple to administer, and which has the potential to prevent unnecessary overdoses across the United States. We are dedicated to ensuring this device reaches the people that need it most as quickly as possible and prevent more opioid related fatalities.'

Industry Context

The announcement comes amid rising opioid-related fatalities, highlighting the urgent need for accessible and effective overdose treatments. Scienture's collaboration with Kindeva positions them to address this critical public health issue by leveraging REZENOPY's higher dose naloxone HCl formulation.

Comparison to Industry Standards

• The Naloxone market is competitive with players like Teva Pharmaceuticals (Narcan Nasal Spray) and Amphastar Pharmaceuticals.
• The total annual sales of Naloxone in the US market is $189 million, unit volume of $10.0 million (eaches) according to IQVIA data (MAT December 2024).
• REZENOPY's 10mg dose is positioned as a higher strength option compared to some other naloxone products, potentially offering increased effectiveness against potent opioids.
• The agreement's financial terms, including milestone payments and net sales share, are typical for pharmaceutical licensing and commercialization agreements.

Stakeholder Impact

• Shareholders: Positive impact due to potential revenue generation and market expansion.
• Patients: Improved access to a life-saving opioid overdose treatment.
• Healthcare Professionals: Additional tool for combating the opioid epidemic.
• Kindeva: Continued manufacturing and potential revenue stream through milestone and profit-sharing payments.

Next Steps

• Formation of a joint steering committee within 30 days of the effective date.
• Transfer of the New Drug Application (NDA) from Kindeva to Scienture.
• Commercial launch of REZENOPY in the U.S.
• Negotiation of a Safety Data Exchange Agreement and Quality Agreement between the parties.

Key Dates